Analysts expect Alnylam Pharmaceuticals, Inc. to report revenue of 1.48 B for Q3 26, against a range of 1.34 B to 1.62 B. The most recent reported quarter, Q2 26, came in at 1.29 B, a 6.8% miss against the 1.38 B consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 500.92 M | 593.17 M | 594.19 M | 773.69 M | 1.25 B | 1.10 B | 1.17 B | 1.29 B | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 619.41 M | 593.45 M | 575.46 M | 709.49 M | 1.11 B | 1.23 B | 1.23 B | 1.47 B | 1.62 B | 1.79 B | 1.62 B | 1.78 B | 1.84 B | 2.08 B | 2.25 B | 1.99 B | ||||||||||
| Low Estimate | 511.47 M | 500.18 M | 535.64 M | 651.62 M | 914.97 M | 1.15 B | 1.14 B | 1.30 B | 1.34 B | 1.55 B | 1.39 B | 1.51 B | 1.69 B | 1.85 B | 1.91 B | 1.78 B | ||||||||||
| Consensus Estimate | 565.44 M | 546.82 M | 555.55 M | 680.56 M | 1.01 B | 1.19 B | 1.18 B | 1.38 B | 1.48 B | 1.67 B | 1.51 B | 1.64 B | 1.76 B | 1.96 B | 2.08 B | 1.88 B |
Analysts expect Alnylam Pharmaceuticals, Inc. to report earnings per share of 1.65 for Q3 26, against a range of 1.60 to 1.70. The most recent reported quarter, Q2 26, came in at 1.21, a 28.0% miss against the 1.68 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.87 | -0.65 | -0.44 | -0.51 | 1.84 | 0.82 | 1.51 | 1.21 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -0.89 | -0.59 | -0.85 | -0.47 | 0.58 | 1.28 | 0.92 | 1.77 | 1.70 | 2.42 | 2.09 | 2.59 | 3.21 | 3.31 | 2.47 | 2.86 | ||||||||||
| Low Estimate | -1.03 | -0.65 | -1.03 | -0.57 | 0.48 | 1.14 | 0.76 | 1.59 | 1.60 | 2.02 | 1.91 | 2.23 | 2.65 | 3.11 | 2.29 | 2.50 | ||||||||||
| Consensus Estimate | -0.96 | -0.62 | -0.94 | -0.52 | 0.53 | 1.21 | 0.84 | 1.68 | 1.65 | 2.22 | 2.00 | 2.41 | 2.93 | 3.21 | 2.38 | 2.68 |
Pull Wall Street consensus for Alnylam Pharmaceuticals, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=ALNY&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "ALNY", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=ALNY&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();